MX2020009711A - Combinacion de quinolin-4-carboxamidas y derivados de benzonaftiridina como combinacion de farmacos antipaludicos. - Google Patents
Combinacion de quinolin-4-carboxamidas y derivados de benzonaftiridina como combinacion de farmacos antipaludicos.Info
- Publication number
- MX2020009711A MX2020009711A MX2020009711A MX2020009711A MX2020009711A MX 2020009711 A MX2020009711 A MX 2020009711A MX 2020009711 A MX2020009711 A MX 2020009711A MX 2020009711 A MX2020009711 A MX 2020009711A MX 2020009711 A MX2020009711 A MX 2020009711A
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- quinoline
- carboxamides
- prodrug
- pharmaceutically acceptable
- Prior art date
Links
- 239000003430 antimalarial agent Substances 0.000 title abstract 2
- BJVCSICIEDHBNI-UHFFFAOYSA-N benzo[b][1,8]naphthyridine Chemical class N1=CC=CC2=CC3=CC=CC=C3N=C21 BJVCSICIEDHBNI-UHFFFAOYSA-N 0.000 title 1
- LEWDKQKVAFOMPI-UHFFFAOYSA-N quinoline-4-carboxamide Chemical class C1=CC=C2C(C(=O)N)=CC=NC2=C1 LEWDKQKVAFOMPI-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000004480 active ingredient Substances 0.000 abstract 3
- 239000000651 prodrug Substances 0.000 abstract 3
- 229940002612 prodrug Drugs 0.000 abstract 3
- WRXNJTBODVGDRY-UHFFFAOYSA-N 2-pyrrolidin-1-ylethanamine Chemical compound NCCN1CCCC1 WRXNJTBODVGDRY-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- DJUFPMUQJKWIJB-UHFFFAOYSA-N pyronaridine Chemical compound C12=NC(OC)=CC=C2N=C2C=C(Cl)C=CC2=C1NC(C=C(CN1CCCC1)C=1O)=CC=1CN1CCCC1 DJUFPMUQJKWIJB-UHFFFAOYSA-N 0.000 abstract 2
- 229950011262 pyronaridine Drugs 0.000 abstract 2
- 230000000078 anti-malarial effect Effects 0.000 abstract 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 abstract 1
- 229960004191 artemisinin Drugs 0.000 abstract 1
- 229930101531 artemisinin Natural products 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se relaciona con una combinación que comprende, como primer ingrediente activo, (2-pirrolidin-1-il-etil )-amida del ácido 6-fluoro-2-(4-morfolin-4-ilmetil-fenil)-quinolin -4-carboxílico o un profármaco o una sal farmacéuticamente aceptable del mismo y como segundo ingrediente activo pironaridina o un profármaco o sal farmacéuticamente aceptable de la misma. La presente invención también se relaciona con una combinación de tres ingredientes activos antipalúdicos, es decir, (2-pirrolidin-1-il-etil)-amida del ácido 6-fluoro-2-(4-morfolin-4- ilmetil-fenil)-quinolin-4-carboxílico o un profármaco o sal del mismo, pironaridina o una sal farmacéuticamente aceptable de la misma, y artemisinina o sus derivados. La invención además se relaciona con composiciones farmacéuticas que comprenden tal combinación y su uso en el tratamiento y/o prevención de la malaria.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18166769 | 2018-04-11 | ||
| PCT/EP2019/058881 WO2019197367A1 (en) | 2018-04-11 | 2019-04-09 | Combination of quinoline-4-carboxamides and benzonaphthyridine derivatives as antimalarial drug combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009711A true MX2020009711A (es) | 2020-10-07 |
Family
ID=61971934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009711A MX2020009711A (es) | 2018-04-11 | 2019-04-09 | Combinacion de quinolin-4-carboxamidas y derivados de benzonaftiridina como combinacion de farmacos antipaludicos. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11491162B2 (es) |
| EP (1) | EP3773549B1 (es) |
| JP (1) | JP7391036B2 (es) |
| KR (1) | KR102775260B1 (es) |
| CN (1) | CN112020356B (es) |
| AU (1) | AU2019252324B2 (es) |
| BR (1) | BR112020020656A2 (es) |
| CA (1) | CA3096721A1 (es) |
| ES (1) | ES2994600T3 (es) |
| HU (1) | HUE069225T2 (es) |
| IL (1) | IL277409B2 (es) |
| MX (1) | MX2020009711A (es) |
| SG (1) | SG11202009956WA (es) |
| WO (1) | WO2019197367A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3175552A1 (en) * | 2020-04-17 | 2021-10-21 | Merck Patent Gmbh | Crystalline forms of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol and salts thereof |
| WO2021257273A1 (en) * | 2020-06-15 | 2021-12-23 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201206280D0 (en) * | 2012-04-10 | 2012-05-23 | Univ Dundee | Anti-malarial agents |
-
2019
- 2019-04-09 JP JP2020555331A patent/JP7391036B2/ja active Active
- 2019-04-09 AU AU2019252324A patent/AU2019252324B2/en active Active
- 2019-04-09 KR KR1020207031920A patent/KR102775260B1/ko active Active
- 2019-04-09 CN CN201980024772.XA patent/CN112020356B/zh active Active
- 2019-04-09 SG SG11202009956WA patent/SG11202009956WA/en unknown
- 2019-04-09 US US15/733,732 patent/US11491162B2/en active Active
- 2019-04-09 MX MX2020009711A patent/MX2020009711A/es unknown
- 2019-04-09 CA CA3096721A patent/CA3096721A1/en active Pending
- 2019-04-09 WO PCT/EP2019/058881 patent/WO2019197367A1/en not_active Ceased
- 2019-04-09 EP EP19715924.7A patent/EP3773549B1/en active Active
- 2019-04-09 BR BR112020020656-3A patent/BR112020020656A2/pt unknown
- 2019-04-09 HU HUE19715924A patent/HUE069225T2/hu unknown
- 2019-04-09 ES ES19715924T patent/ES2994600T3/es active Active
- 2019-04-09 IL IL277409A patent/IL277409B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11491162B2 (en) | 2022-11-08 |
| EP3773549A1 (en) | 2021-02-17 |
| JP2021521147A (ja) | 2021-08-26 |
| IL277409A (en) | 2020-11-30 |
| IL277409B2 (en) | 2025-03-01 |
| US20210023087A1 (en) | 2021-01-28 |
| EP3773549B1 (en) | 2024-08-28 |
| ES2994600T3 (en) | 2025-01-27 |
| AU2019252324A1 (en) | 2020-10-01 |
| CN112020356A (zh) | 2020-12-01 |
| JP7391036B2 (ja) | 2023-12-04 |
| WO2019197367A1 (en) | 2019-10-17 |
| KR20200143703A (ko) | 2020-12-24 |
| BR112020020656A2 (pt) | 2021-01-12 |
| CN112020356B (zh) | 2024-04-05 |
| KR102775260B1 (ko) | 2025-02-28 |
| SG11202009956WA (en) | 2020-11-27 |
| AU2019252324B2 (en) | 2024-12-19 |
| HUE069225T2 (hu) | 2025-02-28 |
| IL277409B1 (en) | 2024-11-01 |
| CA3096721A1 (en) | 2019-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550341A1 (en) | Niraparib formulations | |
| MX2022013612A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas. | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| MY196599A (en) | Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
| MX2019011491A (es) | Formulaciones de niraparib. | |
| NZ631100A (en) | Soft chewable pharmaceutical products | |
| NZ763123A (en) | Pde9 inhibitor and use thereof | |
| WO2017083304A8 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| EA201992116A1 (ru) | Фармацевтические составы флороглюцинола и триметилфлороглюцинола | |
| PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
| MX2020005287A (es) | Antagonistas novedosos del receptor b2 de bradiquinina. | |
| MX2020010568A (es) | Derivados de urea ciclica fusionada como antagonista de crhr2. | |
| PH12021550389A1 (en) | Pharmaceutical composition comprising antiplatelet agent and gastric acid secretion inhibitor | |
| PH12019500328A1 (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
| PH12019500154A1 (en) | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof | |
| TW200800931A (en) | Novel piperazines as antimalarial agents | |
| EP4272832A3 (en) | Antimicrobial compounds, compositions, and uses thereof | |
| PH12019501642A1 (en) | Novel compounds and their use in the treatment of schistosomiasis | |
| MX2021003508A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| MX2021014830A (es) | Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi. | |
| MX2019014321A (es) | Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| AU2016407426A1 (en) | Triple combination of pure 5-HT6 receptor antagonists, Acetylcholinesterase inhibitors and NMDA receptor antagonist | |
| MY160904A (en) | Piperazines as antimalarial agents | |
| WO2017064652A3 (en) | Low dose oral dipyridamole compositions and uses thereof | |
| JOP20230099A1 (ar) | تركيبات صيدلية |